Program
Olanzapine
Also written as “olanzapine”, “ALKS 3831” and “Olanzapine Tablets 5 mg”.
Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Treatment-Resistant · Fasting · Borderline Personality Disorder, led by 11 companies.
Drug pageOlanzapine: every studyMany companies study it; this page follows only the 54 they lead. All 266 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 360 open or running | phase 4since Apr 30, 2002 | Apr 30, 2002 | none ahead |
| Viatrisits history only | 50 open or running | phase 4since Oct 12, 2005 | Sep 1, 2005 | none ahead |
| Dr. Reddy's Laboratories | 40 open or running | phase 1since Jan 2, 2012 | Jan 2, 2012 | none ahead |
| Abbottits history only | 20 open or running | phase 4since Oct 16, 2003 | Oct 16, 2003 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 3since May 2, 2002 | May 2, 2002 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since May 11, 2014 | May 11, 2014 | none ahead |
| Joint Stock Company "Farmak"its history only | 10 open or running | phase 1since Nov 15, 2021 | Nov 15, 2021 | none ahead |
| Neurelisits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
| Orexigen Therapeuticsits history only | 10 open or running | phase 2since Aug 12, 2008 | Aug 12, 2008 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Mar 27, 2023 | Mar 27, 2023 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 1since Mar 13, 2024 | Mar 13, 2024 | none ahead |
Also a collaborator on its studies: Pfizer and H. Lundbeck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr. Reddy's Laboratories only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 2, 2012First studies: 4 phase 1 studiesFirst studyNCT01503450, NCT01503437, NCT01503424 and 1 more
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Studies
All 4 Dr. Reddy's Laboratories leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01503450Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Dec 2006 | 26 |
| NCT01503437Fasting · India | 1 | Completed | Nov 2006 | 22 |
| NCT01503424Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | Sep 2011 | 48 |
| NCT01503398Fasting · India | 1 | Completed | Sep 2011 | 48 |
How it is read
Names in the registry
- “Olanzapine”, 33 entries
- “olanzapine”, 17 entries
- “ALKS 3831”, 7 entries
- “Olanzapine Tablets 5 mg”, 2 entries
- “Olanzapine OD Tablets 5 mg”, 2 entries
Conditions, from the studies’ own filings
- Schizophrenia, 41 studies
- Bipolar Disorder, 12 studies
- Depressive Disorder, Treatment-Resistant, 2 studies
- Fasting, 2 studies
- Borderline Personality Disorder, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.